118 related articles for article (PubMed ID: 1803863)
21. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni GJ
J Biol Regul Homeost Agents; 1994; 8(3):77-80. PubMed ID: 7754792
[TBL] [Abstract][Full Text] [Related]
22. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
[TBL] [Abstract][Full Text] [Related]
23. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
[TBL] [Abstract][Full Text] [Related]
24. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
[TBL] [Abstract][Full Text] [Related]
25. Melatonin as biological response modifier in cancer patients.
Neri B; de Leonardis V; Gemelli MT; di Loro F; Mottola A; Ponchietti R; Raugei A; Cini G
Anticancer Res; 1998; 18(2B):1329-32. PubMed ID: 9615811
[TBL] [Abstract][Full Text] [Related]
26. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
[TBL] [Abstract][Full Text] [Related]
28. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
29. Is there a role for melatonin in supportive care?
Lissoni P
Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
[TBL] [Abstract][Full Text] [Related]
30. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
32. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G
Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
[TBL] [Abstract][Full Text] [Related]
33. Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
Lissoni P; Rovelli F; Barni S; Ardizzoia A; Pittalis S; Tisi E; Perlangeli V; Tancini G
Biol Chem Hoppe Seyler; 1992 Dec; 373(12):1217-22. PubMed ID: 1292506
[TBL] [Abstract][Full Text] [Related]
34. Pineal-opioid system interactions in the control of immunoinflammatory responses.
Lissoni P; Barni S; Tancini G; Fossati V; Frigerio F
Ann N Y Acad Sci; 1994 Nov; 741():191-6. PubMed ID: 7825805
[TBL] [Abstract][Full Text] [Related]
35. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):198-200. PubMed ID: 17451889
[TBL] [Abstract][Full Text] [Related]
36. [Mononuclear cell activation in Crohn's disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors].
Duclos B; Reimund JM; Lang JM; Coumaros G; Chamouard P; Lehr L; Baumann R; Koehl C; Weill JP
Gastroenterol Clin Biol; 1990; 14(1):22-7. PubMed ID: 2311849
[TBL] [Abstract][Full Text] [Related]
37. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
Lissoni P; Barni S; Rovelli F; Brivio F; Ardizzoia A; Tancini G; Conti A; Maestroni GJ
Eur J Cancer; 1993; 29A(2):185-9. PubMed ID: 8422280
[TBL] [Abstract][Full Text] [Related]
38. Cortisol response to an acute injection of IL-2 in healthy subjects and cancer patients: a first immunoneuroendocrine standardized clinical test to explore the interactions between immune and neuroendocrine systems.
Lissoni P; Messina G; Brivio F; Rovelli F; Di Fede G; Mainini E; Veronese E
J Biol Regul Homeost Agents; 2005; 19(3-4):141-4. PubMed ID: 16602629
[TBL] [Abstract][Full Text] [Related]
39. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
[TBL] [Abstract][Full Text] [Related]
40. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
